JP2015517979A - 慢性閉塞性肺疾患の治療法 - Google Patents
慢性閉塞性肺疾患の治療法 Download PDFInfo
- Publication number
- JP2015517979A JP2015517979A JP2014558957A JP2014558957A JP2015517979A JP 2015517979 A JP2015517979 A JP 2015517979A JP 2014558957 A JP2014558957 A JP 2014558957A JP 2014558957 A JP2014558957 A JP 2014558957A JP 2015517979 A JP2015517979 A JP 2015517979A
- Authority
- JP
- Japan
- Prior art keywords
- dna
- subject
- streptolysin
- treatment
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title description 29
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title description 7
- 108010075210 streptolysin O Proteins 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 38
- 230000007883 bronchodilation Effects 0.000 claims abstract description 6
- 208000006673 asthma Diseases 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 15
- 229940124630 bronchodilator Drugs 0.000 claims description 13
- 206010006482 Bronchospasm Diseases 0.000 claims description 10
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 6
- 208000014181 Bronchial disease Diseases 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008121 dextrose Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 17
- 239000000168 bronchodilator agent Substances 0.000 description 11
- 210000003097 mucus Anatomy 0.000 description 11
- 238000013125 spirometry Methods 0.000 description 11
- 208000000059 Dyspnea Diseases 0.000 description 10
- 206010013975 Dyspnoeas Diseases 0.000 description 10
- 206010006451 bronchitis Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 206010014561 Emphysema Diseases 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 241000283086 Equidae Species 0.000 description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010006458 Bronchitis chronic Diseases 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 208000007451 chronic bronchitis Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 201000009890 sinusitis Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 4
- 230000007885 bronchoconstriction Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960004017 salmeterol Drugs 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229940090167 advair Drugs 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 208000018631 connective tissue disease Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 208000033116 Asbestos intoxication Diseases 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000001708 Dupuytren contracture Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000004362 Penile Induration Diseases 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 208000020758 Peyronie disease Diseases 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 206010003441 asbestosis Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 208000030175 lameness Diseases 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 229940046810 spiriva Drugs 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010035600 Pleural fibrosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010067269 Uterine fibrosis Diseases 0.000 description 1
- 206010051513 Viral sinusitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 208000030346 palmar fibromatosis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 229940125390 short-acting beta agonist Drugs 0.000 description 1
- 229940125387 short-acting bronchodilator Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940035073 symbicort Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
SLOタンパク質の天然のアミノ酸配列:
MSNKKTFKKYSRVAGLLTAALIIGNLVTANAESNKQNTASTETTTTNEQPKPESSELTTEKAGQKTDDMLNSNDMIKLAPKEMPLESAEKEEKKSEDKKKSEEDHTEEINDKIYSLNYNELEVLAKNGETIENFVPKEGVKKADKFIVIERKKKNINTTPVDISIIDSVTDRTYPAALQLANKGFTENKPDAVVTKRNPQKIHIDLPGMGDKATVEVNDPTYANVSTAIDNLVNQWHDNYSGGNTLPARTQYTESMVYSKSQIEAALNVNSKILDGTLGIDFKSISKGEKKVMIAAYKQIFYTVSANLPNNPADVFDKSVTFKELQRKGVSNEAPPLFVSNVAYGRTVFVKLETSSKSNDVEAAFSAALKGTDVKTNGKYSDILENSSFTAVVLGGDAAEHNKVVTKDFDVIRNVIKDNATFSRKNPAYPISYTSVFLKNNKIAGVNNRTEYVETTSTEYTSGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSRNIRIMARECTGLAWEWWRKVIDERDVKLSKEINVNISGSTLSPYSITYK
この実施例による72歳の成人は、喘息歴が30年以上であることが分かり、吸入ステロイド/気管支拡張薬により長年にわたって良好にコントロールされていた。
この実施例による68歳の対象は、45歳の時に初めて喘息および再発性副鼻腔炎/気管支炎と診断された。0日目に、この対象に対して、実施例1の方法による舌下液滴を含むSLOおよびDNAによる治療を開始した。その後の一年間は、この対象は、ウイルス性副鼻腔炎/気管支炎の一症例のみを有したが、抗生物質による治療を必要とするところまでは進行しなかった。良好であった。この対象は、ブデソニドおよびフォルモテロールの組み合わせ(Symbicort(登録商標))160/4.5パフを1日に2回使用した(レスキュー薬をほとんど使用しなかった)。彼女は、約510日目に液滴の摂取を2ヶ月間やめた。スパイロメトリーを570日目に行い、その時に、この対象へのSLOおよびDNA組成物の投与を再開した。
この実施例による72歳の女性は、成人発症喘息(すなわち、高頻度に悪化する慢性喘息)であることが分かった。この対象を、1日に4回、実施例1の舌下投与用のSLO/DNA液滴により治療し、その後1年間、軽度の副鼻腔炎/気管支炎の唯一の発症があったが、対象はすぐに回復した。この対象の喘息は、1日に2回、グルチカソン(gluticasone)とサルメテロール(Advair(登録商標)240/50)の混合物でうまくコントロールされ、レスキュー吸入器はほとんど使用せず、スタミナは十分にあった。この対象は、以前よりもすっきりした感じで、1年間同じ薬に対して良好であることを報告した。
この実施例による51歳の男性は、成人発症喘息、喘息/再発性副鼻腔炎であることが分かり、1日に4回、実施例1の舌下用SLO/DNA液滴により治療した。この対象は、喘息コントロールが大幅に改善し、副鼻腔炎の発症がはるかに減少したと報告した。
この実施例による58歳の男性は、長期の喘息、非常に濃い粘液、再発DME浸出を伴う耳管機能障害であることが分かった。この対象は、彼の病状により完全に身体障害があり、慢性の高用量のプレドニゾンおよびグルチカゾンとサルメテロールの混合物(Advair(登録商標))のレスキューを必要とした。スパイロメトリーデータは、FVC=80%、FEV1=73%と予測された。この対象を、1日に4回、実施例1の舌下用SLO/DNA液滴により治療し、3ヶ月後、この対象は、レスキュー吸入器をほとんど使用しないほど、はるかに改善した。FVC=96%、FEV1=82%と予測された。
この実施例による62歳の女性は、COPD/肺気腫/慢性気管支炎であることが分かった。この対象は、1日に2〜3箱の喫煙者であり、骨粗鬆症および胆嚢疾患を患っており、右肺下葉の肺炎を患っていた。
この実施例によると、ウマ肺気腫を患う30頭の馬を、DNA単独、SLO単独またはDNAとSLOの組み合わせによって治療した。2頭または3頭の馬をSLO単独の投与によって治療しても効果はなかったが、その後、DNAとSLOの組み合わせによる治療は成功した。約10頭の馬は、最初に、DNA単独の投与による治療ではある程度成功したが、DNAをSLOと組み合わせた場合にさらに改善した。残りの馬を、常にDNAとSLOの組み合わせにより治療した。全体的に、対象の75〜80%において陽性反応があった。
Claims (12)
- それを必要とする対象において気管支拡張を誘導するかまたは気管支痙攣の緩和を提供する方法であって、薬学的に許容されるビヒクル中に有効量のストレプトリジンOまたはその生物学的に活性のある断片を含む組成物を、それを必要とする対象に投与する工程を含む方法。
- 前記組成物が、液滴の形態で舌下投与される、請求項1に記載の方法。
- 前記ストレプトリジンOが、水、生理食塩水、アルブミン、またはデキストロースからなる群から選択されるビヒクルで投与される、請求項1に記載の方法。
- 前記ストレプトリジンOが、1日当たり0.0032〜50ユニットの投与量で投与される、請求項1に記載の方法。
- 前記ストレプトリジンOが、配列番号1のアミノ酸79〜571からなる、請求項1に記載の方法。
- 前記組成物が、さらにDNAを含む、請求項1に記載の方法。
- 前記有効量のDNAが、約0.00012mg〜約0.003mgのDNAである、請求項1に記載の方法。
- 前記有効量のDNAが、約0.0003mgのDNAである、請求項1に記載の方法。
- 前記対象が、ヒトである、請求項1に記載の方法。
- 前記対象が、ウマである、請求項1に記載の方法。
- 前記患者が、喘息に罹患している、請求項1に記載の方法。
- 前記組成物が、追加の気管支拡張化合物と併用される、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261603701P | 2012-02-27 | 2012-02-27 | |
US61/603,701 | 2012-02-27 | ||
PCT/US2013/027929 WO2013130538A2 (en) | 2012-02-27 | 2013-02-27 | Method of treating chronic obstructive pulmonary disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015517979A true JP2015517979A (ja) | 2015-06-25 |
JP6021952B2 JP6021952B2 (ja) | 2016-11-09 |
Family
ID=49003531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014558957A Expired - Fee Related JP6021952B2 (ja) | 2012-02-27 | 2013-02-27 | 慢性閉塞性肺疾患の治療法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8980826B2 (ja) |
EP (1) | EP2819690A4 (ja) |
JP (1) | JP6021952B2 (ja) |
AU (1) | AU2013226216B2 (ja) |
CA (1) | CA2864132C (ja) |
IL (1) | IL233568A0 (ja) |
WO (1) | WO2013130538A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018510895A (ja) | 2015-04-08 | 2018-04-19 | ビーチ ツリー ラボ、インコーポレイテッド | 外傷性脳損傷を治療する方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080182789A1 (en) * | 2007-01-30 | 2008-07-31 | Milkhaus Laboratory, Inc. | Method of treating pulmonary fibrosis |
JP2009545330A (ja) * | 2006-08-04 | 2009-12-24 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ぺンシルべニア | Ige依存性疾患を治療するための方法および組成物 |
JP2010500879A (ja) * | 2006-08-15 | 2010-01-14 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Hmw−maa及びその断片を含む組成物、及びその使用方法 |
WO2010102140A1 (en) * | 2009-03-04 | 2010-09-10 | The Trustees Of The University Of Pennsylvania | Compositions comprising angiogenic factors and methods of use thereof |
WO2012002762A2 (ko) * | 2010-06-30 | 2012-01-05 | 성균관대학교 산학협력단 | 알러지성 질환의 치료 및 예방을 위한 펩타이드 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948768A (en) | 1995-04-13 | 1999-09-07 | Milkhaus Laboratory | Treatment of otitis media by sublingual administration of DNA |
WO1996032138A1 (en) | 1995-04-13 | 1996-10-17 | Milkhaus Laboratory, Inc. | Methods for treating respiratory disease |
US6096721A (en) * | 1995-04-13 | 2000-08-01 | Milkhaus Laboratory, Inc. | Method for treating mucositis by sublingual administration of DNA |
US5576289A (en) | 1995-04-13 | 1996-11-19 | Milkhaus Laboratory | Methods for treating motor deficits |
US20030032614A1 (en) * | 1995-04-13 | 2003-02-13 | Mcmichael John | Method of treating respiratory distress using synthetic polynucleic acids |
US5736508A (en) | 1997-03-04 | 1998-04-07 | Milkhaus Laboratory, Inc. | Methods for treatment of scar tissue |
US6998121B2 (en) | 2003-01-23 | 2006-02-14 | Milkhaus Laboratory, Inc. | Method of treatment of connective tissue disorders by administration of streptolysin O |
US6303127B1 (en) | 1997-03-04 | 2001-10-16 | Milkhaus Laboratory, Inc. | Treatment of disease states |
US5798102A (en) | 1997-03-04 | 1998-08-25 | Milkhaus Laboratory, Inc. | Treatment of cardiomyopathy |
EP1212094A2 (en) | 1999-04-23 | 2002-06-12 | St. Jude Medical, Inc. | Delivery of antimicrobial toxins |
US20100144602A1 (en) | 2003-01-23 | 2010-06-10 | Milkhaus Laboratory, Inc. | Methods of Inhibiting Metastatic Cancer by Administration of Streptolysin O |
US7629312B2 (en) | 2003-01-23 | 2009-12-08 | Milkhaus Laboratory, Inc. | Method of treatment of tendonitis by administration of streptolysin O |
US8268326B2 (en) * | 2006-08-15 | 2012-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
-
2013
- 2013-02-27 JP JP2014558957A patent/JP6021952B2/ja not_active Expired - Fee Related
- 2013-02-27 WO PCT/US2013/027929 patent/WO2013130538A2/en active Application Filing
- 2013-02-27 CA CA2864132A patent/CA2864132C/en active Active
- 2013-02-27 EP EP13755255.0A patent/EP2819690A4/en not_active Withdrawn
- 2013-02-27 US US13/778,690 patent/US8980826B2/en active Active
- 2013-02-27 AU AU2013226216A patent/AU2013226216B2/en active Active
-
2014
- 2014-07-09 IL IL233568A patent/IL233568A0/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009545330A (ja) * | 2006-08-04 | 2009-12-24 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ぺンシルべニア | Ige依存性疾患を治療するための方法および組成物 |
JP2010500879A (ja) * | 2006-08-15 | 2010-01-14 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Hmw−maa及びその断片を含む組成物、及びその使用方法 |
US20080182789A1 (en) * | 2007-01-30 | 2008-07-31 | Milkhaus Laboratory, Inc. | Method of treating pulmonary fibrosis |
WO2010102140A1 (en) * | 2009-03-04 | 2010-09-10 | The Trustees Of The University Of Pennsylvania | Compositions comprising angiogenic factors and methods of use thereof |
WO2012002762A2 (ko) * | 2010-06-30 | 2012-01-05 | 성균관대학교 산학협력단 | 알러지성 질환의 치료 및 예방을 위한 펩타이드 |
Non-Patent Citations (1)
Title |
---|
JPN6015033410; Allergol. et Immunopathol. 28(6), 2000, p.307-309 * |
Also Published As
Publication number | Publication date |
---|---|
AU2013226216A1 (en) | 2014-07-31 |
IL233568A0 (en) | 2014-08-31 |
WO2013130538A2 (en) | 2013-09-06 |
US20130225480A1 (en) | 2013-08-29 |
CA2864132C (en) | 2019-07-16 |
WO2013130538A3 (en) | 2015-03-12 |
JP6021952B2 (ja) | 2016-11-09 |
EP2819690A2 (en) | 2015-01-07 |
EP2819690A4 (en) | 2016-07-06 |
CA2864132A1 (en) | 2013-09-06 |
US8980826B2 (en) | 2015-03-17 |
AU2013226216B2 (en) | 2016-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5247265B2 (ja) | 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用 | |
Jones et al. | Quality of life changes in COPD patients treated with salmeterol. | |
Keam et al. | Tiotropium bromide: a review of its use as maintenance therapy in patients with COPD | |
JP2014525471A (ja) | 咳および咳発作の治療 | |
JP2022520990A (ja) | 呼吸器疾患の治療の方法 | |
US20080261932A1 (en) | Methods and compositions for the prevention and/or treatment of an exacerbation of asthma | |
US20040009963A1 (en) | Use of salmeterol and fluticasone propionate combination | |
US6100244A (en) | Method for treating respiratory distress by sublingual administration of DNA | |
JP6021952B2 (ja) | 慢性閉塞性肺疾患の治療法 | |
CA2323213C (en) | Treatment of respiratory disease and otitis media | |
JP6013450B2 (ja) | 慢性閉塞性肺疾患改善剤 | |
CA3029621A1 (en) | Compositions and methods for treatment of copd | |
CN116033900A (zh) | 治疗冠状病毒暴露所致疾病的方法 | |
JP2013511528A (ja) | 喘息の急性憎悪の治療及びそれに罹患した患者の入院の可能性の低減 | |
JP5265580B2 (ja) | 慢性閉塞性肺疾患治療剤 | |
Mason | American Thoracic Society 2019 International Conference. Dallas, Texas, USA-May 17-22, 2019 | |
WO2021211006A1 (en) | Inhaled hexapeptide for treating interleukin-6 related respiratory diseases | |
TW202404944A (zh) | 呼吸器官疾病治療劑 | |
JP2023553290A (ja) | 慢性閉塞性肺疾患、喘息、肺炎、気管支炎、嚢胞性線維症、肺水腫、間質性肺疾患、サルコイドーシス、特発性肺胞線維症、急性呼吸窮迫症候群、および肺動脈性肺高血圧症を治療するための方法および組成物 | |
WO2023031753A2 (en) | Nebulization composition comprising tiotropium and its method of administration | |
JPWO2017177966A5 (ja) | ||
JPWO2022040782A5 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150825 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160803 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160803 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161004 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6021952 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |